Summary of Invention
Actinonin, an antibiotic and CD13/aminopeptidase N inhibitor, has been shown to be cytotoxic to human tumor cell lines in vitro and to have antitumor effects on mouse leukemia in vivo. Actinonin inhibits growth of human leukemia and lymphoma cells (NB4, HL60, RAJI, and DAUDI) with an IC50 of about 2-5 
g/mL.
In vivo, using the syngeneic AKR mouse leukemia model, actinonin showed dose-dependent antitumor effects with a significant survival advantage at a dose of 100 g. Moreover, anticancer activity was seen in vivo without significant toxicity. The antiproliferative effects of actinonin on the tumor cells are not mediated by inhibition of CD13/aminopeptidase N.
Advantages
This invention provides a novel method of treating cancers using actinonin.
Areas of Application
Therapeutic drug.
Stage of Development
Animal studies in progress.
Lead Inventor
Dr. David A. Scheinberg
Patent Information
US patent prosecution ongoing.
References
Xu Y, et al. Clin Cancer Res. 4:171-6 (1998).
Related Invention
SK1027. Peptide deformylase is a target of actinonin's antitumor activity.
Contact Information
Viviane Martin, PhD
Tel: 212-639-6181; Fax: 212-717-3439
E-mail: martinv@mskcc.org
